Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cara Therapeutics has announced that the US Patent and Trademark Office has issued new patent under its Accelerated Examination Program.
Subscribe to our email newsletter
The patent covers Cara’s second generation, peripherally-selective kappa opioid receptor agonist compounds.
These compounds include CR845, currently completing a Phase I clinical trial and in development for injectable and oral delivery for the treatment of acute and chronic pain of visceral, inflammatory and neuropathic origin, and for the treatment of pruritis, a common disorder associated with several diseases and conditions.